MBX
MBX Biosciences, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$60.14-4.42%
Price as of Jul 20, 2026
MBX financials
MBX Biosciences, Inc. Common Stock financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $248.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | -$248.0K | $0.00 | $0.00 | $0.00 |
| Operating expenses | $98.1M | $68.2M | $35.3M | $25.2M |
| Operating income | -$98.1M | -$68.2M | -$35.3M | -$25.2M |
| Net income | -$87.0M | -$61.9M | -$32.6M | -$26.1M |
| EBITDA | -$86.7M | -$61.7M | -$32.4M | -$25.7M |
| Basic EPS | $-2.38 | $-1.85 | $-1.02 | $-0.82 |
| Diluted EPS | $-2.38 | $-1.85 | $-1.02 | $-0.82 |
| Balance sheet | ||||
| Cash & equivalents | $75.3M | $49.4M | $30.5M | $24.2M |
| Total assets | $385.1M | $268.5M | $84.2M | $45.1M |
| Total liabilities | $15.9M | $11.1M | $156.6M | $87.7M |
| Stockholders’ equity | $369.2M | $257.4M | -$72.5M | -$42.6M |
| Total debt | $596.0K | $171.0K | $324.0K | $461.0K |
| Net debt | -$74.7M | -$49.2M | -$30.2M | -$23.7M |
| Cash flow | ||||
| Operating cash flow | -$79.9M | -$54.7M | -$32.0M | -$23.1M |
| Capital expenditure | -$1.9M | -$874.0K | -$129.0K | -$441.0K |
| Free cash flow | -$81.9M | -$55.6M | -$32.1M | -$23.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |